These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3275750)

  • 1. Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study.
    Hvizdala EV; Berard C; Callihan T; Falletta J; Sabio H; Shuster JJ; Sullivan M; Wharam MD
    J Clin Oncol; 1988 Jan; 6(1):26-33. PubMed ID: 3275750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
    Sullivan MP; Boyett J; Pullen J; Crist W; Doering EJ; Trueworthy R; Hvizdala E; Ruymann F; Steuber CP
    Cancer; 1985 Jan; 55(2):323-36. PubMed ID: 3880656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol.
    Vecchi V; Serra L; Pession A; Rosito P; Paolucci P; Burnelli R; Vivarelli F; Mancini AF; Paolucci G
    Pediatr Hematol Oncol; 1986; 3(3):217-28. PubMed ID: 3153234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
    Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Uckun FM; Bleyer WA
    Cancer; 1998 Feb; 82(3):600-12. PubMed ID: 9452280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Non-Hodgkinś lymphoma in childhood, preliminary results of the LSA2 L2 protocol modified by high-dose methotrexate].
    Prats Viñas J; Gallego Melcón S; Pérez Payarols J; Macía Martí J; Sánchez de Toledo J
    An Esp Pediatr; 1987 Jan; 26(1):15-21. PubMed ID: 3826937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [non-Hodgkin's lymphoma treated with modified LSA2-L2 protocol--a clinical experience and case report].
    Chiou SS; Chang TT; Perng JJ; Chen TS
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Jun; 3(6):419-24. PubMed ID: 3483004
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors of prognostic importance in childhood non-Hodgkin's lymphoma treated with two modified LSA2-L2 protocols. A multivariate analysis approach.
    de Andrea ML; de Camargo B; Correa Alves A; Machado JC; Franco EL
    Cancer; 1988 Jul; 62(2):240-50. PubMed ID: 3383125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study.
    Falletta JM; Shuster JJ; Crist WM; Pullen DJ; Borowitz MJ; Wharam M; Patterson R; Foreman E; Vietti TJ
    Leukemia; 1992 Jun; 6(6):541-6. PubMed ID: 1602793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of modified LSA2-L2 protocol with moderate-dose MTX therapy in children with untreated non-Hodgkin's lymphoma].
    Shimamoto Y; Imai S; Endo N
    Gan To Kagaku Ryoho; 1992 Mar; 19(3):395-8. PubMed ID: 1543367
    [No Abstract]   [Full Text] [Related]  

  • 10. The treatment of localized non-Hodgkin's lymphoma in children: a report from the Children's Cancer Study Group.
    Jenkin RD; Anderson JR; Chilcote RR; Coccia PF; Exelby PR; Kersey JH; Kushner JH; Meadows AT; Siegel SE; Sposto R
    J Clin Oncol; 1984 Feb; 2(2):88-97. PubMed ID: 6366148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.
    Tubergen DG; Krailo MD; Meadows AT; Rosenstock J; Kadin M; Morse M; King D; Steinherz PG; Kersey JH
    J Clin Oncol; 1995 Jun; 13(6):1368-76. PubMed ID: 7751881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2).
    Anderson JR; Wilson JF; Jenkin DT; Meadows AT; Kersey J; Chilcote RR; Coccia P; Exelby P; Kushner J; Siegel S; Hammond D
    N Engl J Med; 1983 Mar; 308(10):559-65. PubMed ID: 6338381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospectively randomized clinical trial of three intensive chemotherapy regimens for the treatment of advanced unfavorable histology non-Hodgkin's lymphoma.
    O'Connell MJ; Harrington DP; Earle JD; Johnson GJ; Glick JH; Carbone PP; Creech RH; Neiman RS; Mann RB; Silverstein MN
    J Clin Oncol; 1987 Sep; 5(9):1329-39. PubMed ID: 2442322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.
    Sullivan MP; Brecher M; Ramirez I; Ragab A; Hvizdala E; Pullen J; Shuster J; Berard C; Crist W; Vietti T
    Am J Pediatr Hematol Oncol; 1991; 13(3):288-95. PubMed ID: 1793154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
    Mora J; Filippa DA; Qin J; Wollner N
    Cancer; 2003 Sep; 98(6):1283-91. PubMed ID: 12973853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonlymphoblastic lymphoma in children--histology and stage-related response to therapy: a Pediatric Oncology Group study.
    Hvizdala EV; Berard C; Callihan T; Falletta J; Sabio H; Shuster JJ; Sullivan M; Wharam MD
    J Clin Oncol; 1991 Jul; 9(7):1189-95. PubMed ID: 2045859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Pullen J; Boyett J; Shuster J; Crist W; Land V; Frankel L; Iyer R; Backstrom L; van Eys J; Harris M
    J Clin Oncol; 1993 May; 11(5):839-49. PubMed ID: 8487048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study).
    Pullen DJ; Sullivan MP; Falletta JM; Boyett JM; Humphrey GB; Starling KA; Land VJ; Dyment PG; Vats T; Duncan MH
    Blood; 1982 Nov; 60(5):1159-68. PubMed ID: 6982085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.